Riding the Gene Therapy Rollercoaster Into 2026

Abstract

Get full access to this article

View all access options for this article.

References

Gromova

Vaggelas

Dallmann

Seimetz

. Biomarkers: opportunities and challenges for drug development in the current regulatory landscape. Biomark Insights. 2020;15:1177271920974652. doi:10.1177/1177271920974652

DiMasi

Grabowski

Hansen

. Innovation in the pharmaceutical industry: new estimates of R&D costs. J Health Econ. 2016;47:20-33. doi:10.1016/j.jhealeco.2016.01.012

Wagner

. Strategic approach to fit-for-purpose biomarkers in drug development. Annu Rev Pharmacol Toxicol. 2008;48:631-651. doi:10.1146/annurev.pharmtox.48.113006.094611

Carrasco-Zanini

Pietzner

Davitte

, et al. Proteomic signatures improve risk prediction for common and rare diseases. Nat Med. 2024;30:2489-2498. doi:10.1038/s41591-024-03142-z

Parra

Villarroel-Espindola

Behrens

, et al. Multi-omics analysis reveals immune features associated with immunotherapy benefit in patients with squamous cell lung cancer from Phase III Lung-MAP S1400I trial. Clin Cancer Res. 2024;30(8):1655-1668. doi:10.1158/1078-0432.CCR-23-0251

Zannad

Ferreira

Pocock

, et al. Effect of empagliflozin on circulating proteomics in heart failure: mechanistic insights into the EMPEROR programme. Eur Heart J. 2022;43(48):4991-5002. doi:10.1093/eurheartj/ehac495